Nautilus Biotechnology reported Q2 2025 financial results and highlighted progress in developing its proteome-scale single-molecule proteomics platform, targeting a 2026 launch. The company published data demonstrating the application of its technology for detailed analysis of tau protein proteoforms relevant to Alzheimer’s disease, suggesting targeted assays as an alternative path to commercialization. Early experiments with an evolved platform configuration are underway, while probe optimization continues. Although the launch timeline remains subject to delays, targeted proteomics niche usage appears promising as a near-term business strategy.